101 patents
Utility
Glucocorticoid receptor modulators to treat cervical cancer
30 May 23
Methods for treating a subject having a cancerous tumor are disclosed.
Hazel Hunt
Filed: 2 Dec 20
Utility
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
16 May 23
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).
Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
Filed: 28 Jul 21
Utility
Glucocorticoid receptor modulators to treat pancreatic cancer
9 May 23
Hazel Hunt, Thaddeus S. Block
Filed: 21 Oct 20
Utility
Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator
27 Apr 23
Andreas Moraitis
Filed: 20 Dec 22
Utility
Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor Modulators
30 Mar 23
Andreas G. Moraitis
Filed: 9 Nov 22
Utility
Intermittent Dosing of Glucocorticoid Receptor Modulators for the Treatment of Ovarian and Other Cancers
23 Mar 23
Stacie Shepherd, Joseph K. Belanoff
Filed: 2 Sep 22
Utility
Systems and methods of managing treatment of a chronic condition by symptom tracking
21 Mar 23
Devices, systems, and methods for use in managing treatment of a chronic disorder with pharmaceutical or therapeutic compounds by tracking symptoms associated with the disorder.
Steven Lo, David Penake, John Lyons, Lisa Saginian
Filed: 16 Apr 18
Utility
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
28 Feb 23
Andreas Moraitis
Filed: 9 Jun 21
Utility
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
28 Feb 23
The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
Joseph K. Belanoff, Hazel Hunt, Onno C. Meijer, José van den Heuvel
Filed: 3 Dec 20
Utility
Treatment of Adrenocortical Carcinoma with Selective Glucocorticoid Receptor Modulators (SGRMS) and Antibody Checkpoint Inhibitors
23 Feb 23
Methods and compositions for treating a subject suffering from adrenocortical carcinoma and having excess cortisol are disclosed.
Andrew Greenstein, Andreas Grauer, Stacie Shepherd
Filed: 26 Jan 21
Utility
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
14 Feb 23
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
Filed: 12 Jan 21
Utility
Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound
2 Feb 23
Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-(1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs).
Ian Scott, Travis Lemons, Yip-Fong Chia
Filed: 22 Sep 22
Utility
Quaternary Indazole Glucocorticoid Receptor Antagonists
2 Feb 23
The present disclosure provides compounds of Formula I or II.
Hazel Hunt, Lorna DUFFY, Ian STRUTT, Morgan JOUANNEAU, Thomas HORNSBY, Mark MILLS, Andrew William PHILLIPS, Jon-Paul WARD
Filed: 21 Jun 21
Utility
Octahydro fused azadecalin glucocorticoid receptor modulators
24 Jan 23
The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
Hazel Hunt, Iain Walters, Benoit Gourdet
Filed: 12 Jan 21
Utility
Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
10 Jan 23
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.
Hazel Joan Hunt, Lorraine Donaghy, Keith Lorimer, Nathan Jay Dixon, Jeffrey Mark Dener
Filed: 5 May 21
Utility
Pyrimidine cyclohexenyl glucocorticoid receptor modulators
3 Jan 23
The present invention provides a class of pyrimidinedione cyclohexenyl compounds and methods of using these compounds as glucocorticoid receptor modulators.
Hazel Hunt, Damien Francis Philippe Crepin, Joseph Thomas Hill-Cousins, Thomas Matthew Baker, Lorna Duffy
Filed: 3 Jun 19
Utility
Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators
13 Dec 22
Andreas G. Moraitis
Filed: 20 Dec 19
Utility
Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders
24 Nov 22
Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis).
Ada Lee, Andreas Grauer, Joseph Belanoff
Filed: 4 May 22
Utility
Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
11 Oct 22
Disclosed herein are novel formulations containing relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone) that are suitable for administration, including oral administration, to patients suffering from disorders amenable to treatment by glucocorticoid receptor modulators (GRMs).
Ian Scott, Travis Lemons, Yip-Fong Chia
Filed: 18 Dec 19
Utility
Optimizing Mifepristone Absorption
11 Aug 22
The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration.
Joe Belanoff, Robert Roe, Caroline Loewy
Filed: 20 Apr 22